Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (hepatocytes) | 0.10 |
| chemistry Open Targets | compounds already reach it: argatroban, dabigatran, bivalirudin +11 | 1.00 |
| trials ClinicalTrials.gov | 6 Parkinson's trials, 0 stopped | 1.00 |
| literature PubMed | 140 Parkinson's papers of 41,871 | 0.35 |
| pathways Reactome | 17 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 4859
Sealed predictions
- F2 in dopamine neurons, braak+0.02 (p 0.964) → +0.09 (p 0.820)receipt 4867
Swarm cases
receipt 4867: F2 in dopamine neurons, braak
- power
- full sample -0.12 (p 0.640, n 18), 95% CI -0.55 to +0.37. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.12 (p 0.640, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.16 (p 0.515, n 18). could be the mix.
- skeptic
- leave-one-out range -0.28 to -0.03, sign flips 0; without severely affected donors -0.12 (p 0.640, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for F2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts